What is Zacks Research’s Estimate for RDY FY2026 Earnings?

Dr. Reddy’s Laboratories Ltd (NYSE:RDY) – Zacks Research reduced their FY2026 EPS estimates for shares of Dr. Reddy’s Laboratories in a note issued to investors on Wednesday, February 11th. Zacks Research analyst Team now expects that the company will earn $0.64 per share for the year, down from their prior estimate of $0.69. The consensus estimate for Dr. Reddy’s Laboratories’ current full-year earnings is $0.80 per share. Zacks Research also issued estimates for Dr. Reddy’s Laboratories’ Q4 2026 earnings at $0.09 EPS, Q2 2027 earnings at $0.17 EPS, Q3 2027 earnings at $0.13 EPS, Q4 2027 earnings at $0.09 EPS, FY2027 earnings at $0.56 EPS, Q3 2028 earnings at $0.16 EPS and FY2028 earnings at $0.63 EPS.

Dr. Reddy’s Laboratories (NYSE:RDY) last posted its quarterly earnings results on Wednesday, January 21st. The company reported $0.16 EPS for the quarter, hitting analysts’ consensus estimates of $0.16. The business had revenue of $969.81 million during the quarter, compared to analysts’ expectations of $963.84 million. Dr. Reddy’s Laboratories had a return on equity of 15.89% and a net margin of 16.41%.

Separately, Weiss Ratings raised Dr. Reddy’s Laboratories from a “hold (c+)” rating to a “buy (b-)” rating in a report on Friday, January 30th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $16.90.

Dr. Reddy’s Laboratories Stock Performance

Shares of NYSE RDY opened at $14.11 on Thursday. The company has a current ratio of 1.88, a quick ratio of 1.38 and a debt-to-equity ratio of 0.03. Dr. Reddy’s Laboratories has a 12 month low of $12.26 and a 12 month high of $16.17. The stock has a 50 day moving average of $13.78 and a 200-day moving average of $14.01. The company has a market capitalization of $11.78 billion, a P/E ratio of 18.32, a P/E/G ratio of 13.00 and a beta of 0.35.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in RDY. Westside Investment Management Inc. acquired a new stake in shares of Dr. Reddy’s Laboratories during the 2nd quarter worth approximately $35,000. Larson Financial Group LLC lifted its stake in Dr. Reddy’s Laboratories by 81.5% during the fourth quarter. Larson Financial Group LLC now owns 3,173 shares of the company’s stock worth $45,000 after purchasing an additional 1,425 shares during the last quarter. EverSource Wealth Advisors LLC boosted its holdings in shares of Dr. Reddy’s Laboratories by 71.7% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 3,100 shares of the company’s stock valued at $47,000 after purchasing an additional 1,294 shares in the last quarter. Farther Finance Advisors LLC increased its stake in shares of Dr. Reddy’s Laboratories by 217.4% in the 3rd quarter. Farther Finance Advisors LLC now owns 3,568 shares of the company’s stock valued at $50,000 after purchasing an additional 2,444 shares during the last quarter. Finally, Raymond James Financial Inc. bought a new position in shares of Dr. Reddy’s Laboratories in the 2nd quarter valued at $67,000. Institutional investors own 3.85% of the company’s stock.

About Dr. Reddy’s Laboratories

Dr. Reddy’s Laboratories Ltd. is an India‐based multinational pharmaceutical company that develops, manufactures and markets a wide range of pharmaceutical products and services. Established in 1984 by the late Dr. Kallam Anji Reddy, the company has grown into a diversified healthcare enterprise offering generic and proprietary medicines, active pharmaceutical ingredients (APIs), biosimilars and custom research and manufacturing services (CRAMS). Its portfolio spans therapeutic areas such as oncology, cardiovascular care, dermatology, gastroenterology and pain management.

The company’s core activities include the development and commercialization of cost‐effective generic treatments for branded drugs that have lost patent protection, along with in‐house research into innovative molecule development.